ProCE Banner Activity


Diagnosis, Management, and Monitoring of IBD: Early Diagnosis and Individualizing Therapy


An expert in IBD discusses the latest in early diagnosis, individualizing therapy, and monitoring of IBD. This is the first module in a robust IBD Core Curriculum program from Clinical Care Options (CCO) and Practicing Clinicians Exchange (PCE).

Physicians: maximum of 0.25 AMA PRA Category 1 CreditTM

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners: 0.25 Nursing contact hours, includes 0.25 hour of pharmacotherapy credit

Released: January 25, 2023

Expiration: January 24, 2024

No longer available for credit.



Bruce E. Sands

Bruce E. Sands, MD, MS

Dr. Burrill B. Crohn Professor of Medicine
Chief of the Dr. Henry D. Janowitz Division of Gastroenterology

Mount Sinai Hospital
Chief, Division of Gastroenterology
Mount Sinai Health System
Director, Digestive Disease Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by the American Gastroenterological Association and Partners for Advancing Clinical Education, in partnership with Practicing Clinicians Exchange and Clinical Care Options, LLC.

ProCE Banner
ProCE Banner


This educational activity is supported by educational grants from Amgen, Inc., Ferring Pharmaceuticals, Inc., Takeda Pharmaceuticals U.S.A., Inc.

Amgen, Inc.

Ferring Pharmaceuticals, Inc.

Takeda Pharmaceuticals U.S.A., Inc.


Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange

ProCE Banner

Target Audience

This program is intended for the IBD care team including gastroenterologists, advanced practice providers that specialize in gastroenterology, internal medicine and family medicine physicians and advanced practice providers, nurses and other HCPs involved in the care of patients living with IBD.

Program Learning Goal

The goal of this multicomponent, multiformat curriculum is to improve the knowledge and competence of community HCPs who care for patients living with ulcerative colitis and Crohn’s disease.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe early signs and symptoms of IBD to prevent delays in diagnosis and treatment initiation

  • Implement strategies for individualizing initial therapy in patients with IBD based on available agents and guidelines


All faculty and planners participating in continuing education activities sponsored by Partners for Advancing Clinical Education (PACE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PACE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Bruce E. Sands, MD, MS: consultant/advisor/speaker: AbbVie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Fresenius Kabi, Genentech, GlaxoSmithKline, Janssen, Lilly, Merck, Pfizer, Sun Pharma, Takeda, Teva.

The planners and content peer reviewers from Partners for Advancing Clinical Education, the American Gastroenterological Associate, Practicing Clinicians Exchange, and Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Kimberly Kearns, MS, APN-BC as noted below:

Kimberly Kearns, MS, APN-BC: consultant/advisor/speaker: Lilly, Janssen, Salix

Instructions for Credit

Learners wishing to earn CE/CME credit must: 

  1. View the content in its entirety
  2. Relate the content material to the learning objectives 
  3. Complete evaluation form 

The estimated time to complete this activity is 0.25 hour.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The AGA Institute designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 


ANCC Credit Designation
Nursing contact hours: 0.25 , which includes 0.25  hour of pharmacology credit
Nurse Course Advisor: Kimberly Kearns, MS, APN-BC, Duly Health and Care, Hoffman Estates, Illinois

AAPA Credit Designation
Joint AccreditationPartners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until January 24, 2024. PAs should only claim credit commensurate with the extent of their participation. 

PA Course Advisor: Abigail Meyers, PA-C, Mayo Clinic, Rochester, Minnesota